Innoviva (NASDAQ:INVA) Releases Earnings Results

Innoviva (NASDAQ:INVA) posted its quarterly earnings results on Wednesday. The biotechnology company reported $0.57 earnings per share for the quarter, Zacks reports. Innoviva had a net margin of 18.31% and a return on equity of 20.84%.

Innoviva Price Performance

INVA stock opened at $17.90 on Thursday. Innoviva has a one year low of $14.32 and a one year high of $21.28. The company’s fifty day moving average price is $18.04 and its 200-day moving average price is $18.86. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. The company has a market capitalization of $1.12 billion, a PE ratio of 25.94 and a beta of 0.55.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.